Neurocrine Touts Phase III Huntington’s Data, Posts 29% YoY Growth

In support of a New Drug Application, Neurocrine Biosciences on Thursday posted interim results from the ongoing Phase III KINECT-HD2 study showing that its Ingrezza (valbenazine) capsules can improve chorea in patients with Huntington’s disease.